Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition

*Medicine* 2020; 99(26):e20458

Adjuvant rituximab, a potential treatment for the young patient with Graves' hyperthyroidism (RiGD): Study protocol for a single-arm, single-stage, phase II trial

*BMJ Open* 2019; 9(1):e024705

Drooling Reduction Intervention randomised trial (DRI): Comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability

*Archives of Disease in Childhood* 2018; 103(4):371-376

A feasibility study incorporating a pilot randomised controlled trial of oral feeding plus pre-treatment gastrostomy tube versus oral feeding plus as-needed nasogastric tube feeding in patients undergoing chemoradiation for head and neck cancer (TUBE trial): Study protocol

*Pilot and Feasibility Studies* 2016; 2:29

Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma

*European Journal of Cancer* 2016; 55:56-64

A pragmatic approach to the design and calibration of a Bayesian CRM dose finding trial

*Trials* 2015; 16(S2):P210

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia

*Oncotarget* 2015; 6(41):43978-43991

Abstract 4651: Characterization of the clinical pharmacokinetics of actinomycin D and the influence of pharmacogenetic variation in children with cancer

*Cancer Research* 2014; 74(19 Suppl):4651

Abstract 5457: Cytarabine leaves a mutational fingerprint in relapsing leukemia

*Cancer Research* 2014; 74(Suppl 19):5457

Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia

*Leukemia* 2015; 29(2):491-494